BIOMAT Database Logo BIOMAT Database Logo

Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. 1990

R T Schooley, and T C Merigan, and P Gaut, and M S Hirsch, and M Holodniy, and T Flynn, and S Liu, and R E Byington, and S Henochowicz, and E Gubish
Massachusetts General Hospital, Boston.

OBJECTIVE To study the safety and pharmacokinetics and to derive preliminary evidence on surrogate indicators of efficacy of recombinant soluble CD4 (rsCD4) in patients with the acquired immunodeficiency syndrome (AIDS) and advanced AIDS-related complex. METHODS Open label, escalating dosage, phase I-II tolerance trial. METHODS Massachusetts General Hospital, Cedars-Sinai Medical Center, and Stanford University Medical School, three tertiary care institutions and members of the National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. BACKGROUND Cohorts of 3 to 11 patients received rsCD4 by intravenous infusion or intramuscular injection in dosages of up to 30 mg per day for 28 days. RESULTS Recombinant soluble CD4 was tolerated by these patients with no significant clinical or immunologic toxicities. Serum levels of rsCD4 in patients receiving doses of 9 or 30 mg per day administered intramuscularly were in the range of rsCD4 concentrations required to inhibit replication of human immunodeficiency virus 1 (HIV-1) in vitro. A decline in serum HIV-1 p24 antigen was seen in patients receiving 30 mg of rsCD4 daily, but no such changes were noted at lower dosages. CONCLUSIONS Recombinant soluble CD4 is well tolerated by patients with AIDS or advanced AIDS-related complex. Our study has also provided preliminary evidence of antiviral activity of rsCD4 in vivo. Our data suggest that further trials of receptor-based therapies against HIV-1 are warranted.

UI MeSH Term Description Entries
D007273 Injections, Intramuscular Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it. Intramuscular Injections,Injection, Intramuscular,Intramuscular Injection
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency

Related Publications

R T Schooley, and T C Merigan, and P Gaut, and M S Hirsch, and M Holodniy, and T Flynn, and S Liu, and R E Byington, and S Henochowicz, and E Gubish
The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 study.
February 1990, Annals of internal medicine,
R T Schooley, and T C Merigan, and P Gaut, and M S Hirsch, and M Holodniy, and T Flynn, and S Liu, and R E Byington, and S Henochowicz, and E Gubish
2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial.
May 1990, The New England journal of medicine,
R T Schooley, and T C Merigan, and P Gaut, and M S Hirsch, and M Holodniy, and T Flynn, and S Liu, and R E Byington, and S Henochowicz, and E Gubish
A phase I trial of recombinant human interferon-gamma in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome (AIDS).
July 1989, Journal of clinical immunology,
R T Schooley, and T C Merigan, and P Gaut, and M S Hirsch, and M Holodniy, and T Flynn, and S Liu, and R E Byington, and S Henochowicz, and E Gubish
Acquired immunodeficiency syndrome (AIDS) related complex.
September 1986, Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association,
R T Schooley, and T C Merigan, and P Gaut, and M S Hirsch, and M Holodniy, and T Flynn, and S Liu, and R E Byington, and S Henochowicz, and E Gubish
AIDS Clinical Trials Group: phase I/II study of combination 2',3'-dideoxycytidine and zidovudine in patients with acquired immunodeficiency syndrome (AIDS) and advanced AIDS-related complex.
May 1990, The American journal of medicine,
R T Schooley, and T C Merigan, and P Gaut, and M S Hirsch, and M Holodniy, and T Flynn, and S Liu, and R E Byington, and S Henochowicz, and E Gubish
Hyponatremia in hospitalized patients with the acquired immunodeficiency syndrome (AIDS) and the AIDS-related complex.
February 1993, The American journal of medicine,
R T Schooley, and T C Merigan, and P Gaut, and M S Hirsch, and M Holodniy, and T Flynn, and S Liu, and R E Byington, and S Henochowicz, and E Gubish
Gallium Studies in Patients With the Acquired Immunodeficiency Syndrome (AIDS) and the AIDS-Related Complex.
April 1988, The Western journal of medicine,
R T Schooley, and T C Merigan, and P Gaut, and M S Hirsch, and M Holodniy, and T Flynn, and S Liu, and R E Byington, and S Henochowicz, and E Gubish
Plasma fibronectin values in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex.
September 1988, American journal of clinical pathology,
R T Schooley, and T C Merigan, and P Gaut, and M S Hirsch, and M Holodniy, and T Flynn, and S Liu, and R E Byington, and S Henochowicz, and E Gubish
Echocardiographic findings in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex (ARC).
March 1989, Catheterization and cardiovascular diagnosis,
R T Schooley, and T C Merigan, and P Gaut, and M S Hirsch, and M Holodniy, and T Flynn, and S Liu, and R E Byington, and S Henochowicz, and E Gubish
Mucocutaneous findings in acquired immunodeficiency syndrome/AIDS-related complex patients.
April 1987, Journal of the American Academy of Dermatology,
Copied contents to your clipboard!